[
  {
    "ts": null,
    "headline": "Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial",
    "summary": "New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp size and sense of smell in CRSwNP, and lung function and disease control in asthma, with rapid improvements seen as early as 4 weeks Results reinforce the efficacy of Dupixent in treating both upper and lower respiratory diseases by targeting I",
    "url": "https://finnhub.io/api/news?id=1e8b358ea903ccb7cb0c7a994c2c375ea8c605434121c43ea1b6289292827093",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750000860,
      "headline": "Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial",
      "id": 135285682,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp size and sense of smell in CRSwNP, and lung function and disease control in asthma, with rapid improvements seen as early as 4 weeks Results reinforce the efficacy of Dupixent in treating both upper and lower respiratory diseases by targeting I",
      "url": "https://finnhub.io/api/news?id=1e8b358ea903ccb7cb0c7a994c2c375ea8c605434121c43ea1b6289292827093"
    }
  },
  {
    "ts": null,
    "headline": "These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025",
    "summary": "These two S&P 500 stocks, which fell between 18.2% and 26.6% in May, are worth watching.",
    "url": "https://finnhub.io/api/news?id=7335d1ccce8670e2cbf6ab9bf8f85c45b71a40df09d99c6c949ae7f0920f4977",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749995940,
      "headline": "These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025",
      "id": 135286104,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "These two S&P 500 stocks, which fell between 18.2% and 26.6% in May, are worth watching.",
      "url": "https://finnhub.io/api/news?id=7335d1ccce8670e2cbf6ab9bf8f85c45b71a40df09d99c6c949ae7f0920f4977"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis",
    "summary": "Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results from the open-label Phase 4 DISCOVER trial of Dupixent (dupilumab) in treating moderate-to-severe atopic dermatitis/AD in adolescents and adults with skin of color. These findings were presented […]",
    "url": "https://finnhub.io/api/news?id=00d76b1899b6f0fe9ada96c1177d617d4f38503d69792cfa9615e2e949acf0e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749980326,
      "headline": "Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis",
      "id": 135284782,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results from the open-label Phase 4 DISCOVER trial of Dupixent (dupilumab) in treating moderate-to-severe atopic dermatitis/AD in adolescents and adults with skin of color. These findings were presented […]",
      "url": "https://finnhub.io/api/news?id=00d76b1899b6f0fe9ada96c1177d617d4f38503d69792cfa9615e2e949acf0e9"
    }
  }
]